Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics (CRSP) is a clinical-stage biopharmaceutical leader pioneering CRISPR/Cas9 gene editing therapies for serious diseases. This page aggregates official announcements, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and researchers will find timely updates on therapeutic programs targeting hemoglobinopathies, oncology, and autoimmune disorders. Track regulatory milestones, partnership announcements with industry leaders, and financial performance reports. All content is curated to meet investor needs for decision-making clarity.
Key updates include progress in allogeneic CAR-T cell therapies, hemoglobinopathy treatment approvals, and manufacturing scale-up initiatives. Bookmark this page for structured access to CRISPR Therapeutics' latest scientific advancements and business developments.
CRISPR Therapeutics and Nkarta have announced a strategic partnership to co-develop gene-edited cell therapies for cancer. The collaboration will focus on two chimeric antigen receptor (CAR) NK cell product candidates targeting CD70 and a novel NK+T product. Nkarta obtains a license for CRISPR gene editing technology for its NK cell therapies. Both companies will equally share R&D costs and profits, with a three-year exclusivity period for allogeneic, gene-edited NK cells. This partnership aims to accelerate the development of new cancer therapies, leveraging their expertise.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences. The Truist Securities Life Sciences Summit is set for May 5, 2021, at 11:20 a.m. ET. Following that, the 2021 Bank of America Healthcare Conference will occur on May 12, 2021, at 2:00 p.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-presentation. CRISPR Therapeutics focuses on gene-based medicines, leveraging its proprietary CRISPR/Cas9 technology across various disease areas.
CRISPR Therapeutics (Nasdaq: CRSP) announced a Trials in Progress poster presentation for its ongoing Phase 1 CARBON trial at the American Society of Clinical Oncology Annual Meeting. The presentation will cover the safety and efficacy of CTX110™, an allogeneic CAR-T investigational therapy targeting CD19, for treating relapsed or refractory B-cell malignancies. The virtual event will occur from June 4 to 8, 2021, with the poster session scheduled for 9:00 AM ET on June 4.
CRISPR Therapeutics (Nasdaq: CRSP) announced it received Priority Medicines designation from the European Medicines Agency for CTX001™, a gene-edited therapy for transfusion-dependent beta thalassemia (TDT). Over 30 patients have been dosed in ongoing trials, with enrollment completion expected in 2021. The company's financial results for Q1 2021 showed a net loss of $113.2 million, an increase from $69.7 million the previous year, and R&D expenses rose to $90.6 million. CRISPR also amended its agreement with Vertex for CTX001, sharing costs and profits 40/60.
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 – Vertex Pharmaceuticals and CRISPR Therapeutics announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, a CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta thalassemia (TDT). This designation aims to expedite the development and evaluation of innovative therapies.
CTX001 has also received multiple FDA designations and is currently being evaluated in ongoing clinical trials for TDT and severe sickle cell disease (SCD).
Vertex Pharmaceuticals and CRISPR Therapeutics have revised their collaboration agreement for CTX001, a CRISPR/Cas9-based gene editing therapy aimed at treating sickle cell disease and beta-thalassemia. Vertex will lead the development, manufacturing, and commercialization of CTX001, responsible for 60% of program costs and profits. CRISPR will receive a $900 million upfront payment and up to $200 million upon regulatory approval. Vertex sees significant commercial potential in CTX001, having dosed over 30 patients with encouraging clinical results.
CRISPR Therapeutics (Nasdaq: CRSP) announced promising preclinical data from its allogeneic CAR-T program at the AACR Annual Meeting 2021. The study showcased that CAR-T cells with CD70 knockout displayed enhanced potency and persistence compared to conventional CAR-T cells. The research explored the effects of CRISPR/Cas9 gene editing on various checkpoint genes, revealing CD70's superior efficacy. The ongoing clinical trials of CTX130, targeting CD70-expressing tumors, expect to report top-line data in 2021, marking a significant step in cancer treatment innovation.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 a.m. ET. Members of the senior management team will represent the company.
A live webcast will be available on the company's Investors page, with a replay archived for 14 days following the event. CRISPR Therapeutics is focused on developing gene-based medicines using its proprietary CRISPR/Cas9 platform, targeting serious diseases across various fields.
CRISPR Therapeutics (Nasdaq: CRSP) will present a poster at the AACR Annual Meeting, focusing on a novel approach to augment CAR-T cell function through CD70 knockout technology. The presentation is scheduled for April 10, 2021, at 8:30 a.m. ET. This virtual event will showcase advancements in immunology and the potential of CRISPR's gene-editing platform. The company aims to develop transformative medicines for serious diseases, leveraging collaborations with industry leaders like Bayer and Vertex Pharmaceuticals.
CRISPR Therapeutics (Nasdaq: CRSP) announces its participation in two upcoming virtual investor conferences in March 2021. The Barclays Global Healthcare Conference will take place on March 9, 2021, at 10:20 a.m. ET, and the 33rd Annual Roth Conference is scheduled for March 15, 2021, at 1:30 p.m. ET. Investors can access live webcasts through the company's website, with replay available for 14 days post-event. CRISPR Therapeutics is a leader in gene editing, developing transformative medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
